Impact of Forearm Immobilization on Muscle Metabolism in Type 2 Diabetes
The Impact of Short-term Forearm Immobilization on Forearm Muscle Glucose and Amino Acid Metabolism of Volunteers With or Without Type 2 Diabetes
This study is testing how keeping the forearm still for two days affects muscle sugar use and protein balance in people with Type 2 Diabetes compared to healthy individuals.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 26 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Wageningen University Academic / other |
| Locations | 1 site (Wageningen, Gelderland) |
| Trial ID | NCT06750497 on ClinicalTrials.gov |
What this trial studies
This study investigates how short-term immobilization of the forearm affects muscle glucose uptake and amino acid balance in individuals with Type 2 Diabetes (T2D) compared to healthy individuals. Participants will undergo two days of forearm immobilization, simulating local physical inactivity. Measurements of arteriovenous forearm balance will be taken alongside stable isotope tracer infusion to assess metabolic changes before, during, and after the immobilization period.
Who should consider this trial
Good fit: Ideal candidates include males and females aged 18-65 with diagnosed Type 2 Diabetes or healthy individuals without diabetes.
Not a fit: Patients with Type 1 diabetes, cardiovascular diseases, or those on certain medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into metabolic responses to inactivity in T2D, potentially leading to improved management strategies for the condition.
How similar studies have performed: While the specific approach of forearm immobilization in T2D is novel, similar studies on physical inactivity and metabolic responses have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria * Males and females with or without diagnosed type 2 diabetes * Use lifestyle changes, metformin, gliclazide, or a combination thereof as oral glucose-lowering treatments for T2D * Aged 18-80 years at the time of signing informed consent * 18.5 ≥ BMI ≤ 35 kg·m2 Exclusion criteria * Type 1 or a genetic form of diabetes * Any diagnosed cardiovascular (heart) disease or high blood pressure (≥160 mmHg systolic and/or ≥100 mmHg diastolic) * Chronic use of any prescribed or over-the-counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) that interact with muscle substrate metabolism (e.g. selective serotonin reuptake inhibitors) * Consumption of a low-carbohydrate diet * Smoking or chewing tobacco * Known anaemia * Regular use of dietary protein and/or amino acid supplements (\>3 times per week) * Currently involved in a structured progressive resistance training program (\>3 times per week) * A personal or family history of thrombosis (clots) * Any previous motor disorders or inborn errors in muscle and/or lipid metabolism * History of kidney disease * History of liver disease * Pregnant or breastfeeding * History of any drug or alcohol abuse in the past two years * Claustrophobia * Unable to give consent
Where this trial is running
Wageningen, Gelderland
- Wageningen University and Research — Wageningen, Gelderland, Netherlands (Recruiting)
Study contacts
- Study coordinator: Marlou Dirks, PhD
- Email: marlou.dirks@wur.nl
- Phone: +31 317 480 100
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.